Read more

February 06, 2023
4 min watch
Save

VIDEO: Botensilimab, balstilimab combination ‘huge innovation’ in colorectal cancer subset

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In a video interview with Healio, Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, spoke about “the first combination to show efficacy in colorectal cancer in a specialized population.”

Presented at ASCO Gastrointestinal Cancers Symposium, this expanded phase 1a/1b study showed that botensilimab (Agenus), a modified CTLA-4 inhibitor, plus balstilimab (Agenus), a modified PD-1 inhibitor, showed promising clinical activity with durable responses and was well tolerated in heavily pretreated metastatic patients with microsatellite stable colorectal cancer.

“We saw very impressive efficacy ... over 70% of disease control rate, which were people with either minimal growth or minimal shrinkage, and over 20% had objective responses, some of which were near complete responses and many of which are prolonged,” Schlechter said.

Schlechter also noted a randomized phase 2 study has launched. Although he said there are still “several things we have to figure out” about botensilimab, he thinks “we’re going to see a lot from this drug.”

“There’s a lot to come on this drug, but for patients with nonhepatic disease ... this is a huge innovation,” he said. “It’s a very effective combination, a very safe combination when management of toxicity is done carefully, and it really is so much better — in a non-comparative sense — than [trifluridine/tipiracil (Lonsurf; Taiho Oncology, Servier)] or regorafenib [Stivarga, Bayer]. We will see in the randomized phase 2 if that will come to fruition, but as someone who has given a lot of Lonsurf, a lot of regorafenib and a lot of this drug — it’s just in a different league.”

Reference:

  • El-Khoueiry AB, et al. Abstract LBA8. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.